Akkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury
Recruiting
Phase 1
Interventional Study
Radiation-Induced Skin Injury
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 40 (estimated)
- Sponsor
- West China Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a multicenter, open-label, Phase I single-arm clinical trial evaluating the safety and tolerability of a topical AKK probiotic preparation (Akkermansia muciniphila) for the prevention and treatment of radiation-induced skin injury in patients receiving radiotherapy for breast cancer, head and neck cancer (including nasopharyngeal carcinoma). A total of 40 participants are planned to …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of breast cancer, head and neck cancer (including nasopharyngeal carcinoma) receiving radiotherapy
* Age ≥18 years and ≤75 years, any sex
* Signed written informed consent
* Radiation field skin area can be localized and skin inflammation can be assessed
* ECOG perfo…
Contacts
No contact information available.